Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 581 pages

Showing 201 - 250


breast cancer

Impact of 70-Gene Signature on Adjuvant Chemotherapy Decisions in Breast Cancer

In a Dutch observational study reported in the Journal of Clinical Oncology, Kuijer et al found that use of the MammaPrint 70-gene signature (70-GS) test changed physician-intended recommendations to administer adjuvant chemotherapy in half of patients with early-stage estrogen...

breast cancer

Suboptimal BMD Evaluation in Postmenopausal Women With Early-Stage Breast Cancer Receiving Aromatase Inhibitors

In a study reported in the Journal of Oncology Practice, Stratton et al found that most postmenopausal Medicare patients with early-stage breast cancer receiving aromatase inhibitor therapy do not receive recommended bone mineral density (BMD) measurements. Most expert panels recommend BMD...

breast cancer

Association of Metformin Use for Diabetes With Outcomes in HER2-Positive Breast Cancer

In an analysis from the phase III ALTTO trial reported in the Journal of Clinical Oncology, Sonnenblick et al found that among patients receiving adjuvant therapy for HER2-positive breast cancer, those with diabetes who received metformin had better outcomes than those who did not receive...

breast cancer

Cancer Care Ontario and ASCO Clinical Practice Guideline: Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer

As reported in the Journal of Clinical Oncology by Dhesy-Thind, ofJuravinski Cancer Centre, Hamilton Health Sciences, and colleagues, Cancer Care Ontario and ASCO have issued a clinical practice guideline on the use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer. The...

breast cancer

Dutch Study Examines Effect of Internet-Based Cognitive Behavioral Therapy on Sexual Functioning in Breast Cancer Survivors

In a Dutch study reported in the Journal of Clinical Oncology, Hummel et al found that use of an Internet-based cognitive behavioral therapy intervention improved sexual functioning among breast cancer survivors. Study Details In the study, 169 women with a diagnosis of sexual dysfunction from 10 ...

breast cancer

Neoadjuvant Dual HER2 Blockade in HER2-Enriched Early Breast Cancer

In the Spanish phase II PAMELA study reported in The Lancet Oncology, Llombart-Cussac et al found that the HER2-enriched subtype was associated with the highest likelihood of pathologic complete response after neoadjuvant trastuzumab (Herceptin) and lapatinib (Tykerb) without chemotherapy in...

breast cancer

Effect of Scalp Cooling on Hair Loss in Women Receiving Nonanthracycline Chemotherapy for Breast Cancer

In a prospective cohort study reported in JAMA, Rugo et al found that use of a scalp-cooling device reduced hair loss in women receiving nonanthracycline chemotherapy for early-stage breast cancer. Study Details In the study, 101 evaluable patients from 5 U.S. centers with stage I or II breast...

breast cancer

11-Year Follow-up of Adjuvant Trastuzumab in the HERA Trial

In the 11-year follow-up of the HERA trial reported in The Lancet, Cameron et al found that 1 year of trastuzumab (Herceptin) following adjuvant therapy for HER2-positive breast cancer remained associated with improved disease-free and overall survival compared with observation. No additional...

breast cancer

Cholesterol-Lowering Medication Use and Breast Cancer Outcome in the BIG 1-98 Trial

In a study reported in the Journal of Clinical Oncology, Borgquist et al found that use of cholesterol-lowering medication during adjuvant endocrine therapy was associated with a reduced risk of breast cancer recurrence in hormone receptor–positive women in the BIG 1-98 trial. Study Details ...

breast cancer

Chinese Trial Adds Utidelone to Capecitabine in Heavily Pretreated Patients With Metastatic Breast Cancer

In a Chinese phase III trial reported in The Lancet Oncology, Zhang et al found that adding the epothilone analog utidelone to capecitabine prolonged progression-free survival in women with heavily pretreated metastatic breast cancer refractory to both anthracycline and taxane treatment. Study...

breast cancer

Study Finds Suboptimal Use of Adjuvant Endocrine Therapy in Breast Cancer

In a retrospective cohort study reported in JAMA Oncology, Daly et al found that recommended use of adjuvant endocrine therapy for breast cancer improved in the United States between 2004 and 2013 but remains suboptimal. The study included data on 981,729 women with stage I to III breast cancer...

breast cancer

Effect of Scalp-Cooling Device on Hair Loss in Women Receiving Chemotherapy for Breast Cancer

An interim analysis of the SCALP trial, reported in JAMA by Nangia et al, showed that use of a scalp-cooling device significantly reduced hair loss in women receiving chemotherapy for stage I or II breast cancer compared with no scalp cooling. The study was stopped early on the basis of efficacy....

breast cancer

Genetic Testing and Counseling Among Women With Newly Diagnosed Breast Cancer

In a population-based study reported in a research letter in JAMA, Kurian et al found that genetic testing and genetic counseling are suboptimal among women with newly diagnosed breast cancer. Study Details The study involved 2,451 women aged 20 through 79 years diagnosed with stage 0 to II...

breast cancer

Zoledronic Acid Every 12 Weeks vs Every 4 Weeks in Women With Breast Cancer and Bone Metastases

In the phase III OPTIMIZE-2 trial reported in JAMA Oncology, Hortobagyi et al found that an every-12-week schedule of zoledronic acid was noninferior to an every-4-week schedule in terms of skeletal-related event rate in women with bone metastases from breast cancer who were currently receiving...

breast cancer

Residual Cancer Burden, Breast Cancer Phenotype, and Long-Term Prognosis After Neoadjuvant Chemotherapy

In a study reported in the Journal of Clinical Oncology, Symmans et al found that residual cancer burden (RCB) after neoadjuvant chemotherapy was significantly prognostic for long-term outcome across breast cancer subtypes. Study Details The study included 5 patient cohorts from The University of ...

breast cancer

Accelerated Partial-Breast vs Whole-Breast Irradiation After Breast-Conserving Surgery

As reported in The Lancet Oncology by Polgár et al, 5-year late side effects and cosmetic results were similar with accelerated partial-breast irradiation (APBI) with interstitial brachytherapy vs whole-breast irradiation (WBI) after breast-conserving surgery for low-risk invasive and in...

breast cancer

Adjuvant Letrozole vs Anastrozole in Hormone Receptor–Positive Node-Positive Early Breast Cancer

As reported in the Journal of Clinical Oncology by Smith et al, the final results of the phase III FACE trial showed no difference in disease-free or overall survival for adjuvant letrozole vs anastrozole in postmenopausal women with hormone receptor–positive node-positive early breast...

breast cancer

Predicting Acute Cardiac Events in Patients With Breast Cancer Receiving Radiotherapy

In a Dutch study reported in the Journal of Clinical Oncology, van den Bogaard et al found that a model including the volume of the left ventricle receiving 5 Gy (LV-V5) might provide improved prediction of acute cardiac events in patients with breast cancer receiving radiotherapy. Prior findings...

breast cancer

Risk Factors for Estrogen Receptor–Positive and –Negative Breast Cancer

In a study reported in the Journal of the National Cancer Institute, Kerlikowske et al identified risk factors for estrogen receptor–positive and –negative breast cancer using data from the Breast Cancer Surveillance Consortium. The analysis included 1,279,443 women, aged 35 to 74...

breast cancer

Higher Intake of Grilled/Barbecued and Smoked Meat Linked to Reduced Survival After Breast Cancer

In a study reported in the Journal of the National Cancer Institute, Parada et al found that higher intake of grilled/barbecued and smoked meat may be associated with poorer overall survival in breast cancer survivors. Grilled/barbecued and smoked meat, a source of polycyclic aromatic hydrocarbon...

breast cancer

What Influences a Woman’s Decision to Stop Chemopreventive Therapy for Breast Cancer?

In an analysis from the Canadian Cancer Trials Group MAP.3 chemoprevention trial reported in the Journal of Clinical Oncology, Meggetto et al found that worsening of overall menopause-specific quality of life was associated with early discontinuation of study treatment in high-risk postmenopausal...

breast cancer

Disappointing Efficacy of Chemotherapy Guided by Ki67 Level After Neoadjuvant AI Therapy for Breast Cancer

In an analysis in the American College of Surgeons Oncology Group (ACOSOG) Z1031 Trial/Alliance reported in the Journal of Clinical Oncology, Ellis et al found that switching to chemotherapy in patients with elevated Ki67 levels after 2 to 4 weeks of neoadjuvant aromatase inhibitor therapy resulted ...

breast cancer

Improved Survival With Higher Tumor-Infiltrating Lymphocyte Values in Advanced HER2-Positive Breast Cancer

In a retrospective analysis of the phase III CLEOPATRA trial reported in The Lancet Oncology, Luen et al found that higher baseline tumor-infiltrating lymphocyte levels were associated with improved overall survival among patients with advanced HER2-positive breast cancer receiving trastuzumab...

breast cancer

ASCO Makes No Changes to 2014 Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer

As reported in the Journal of Clinical Oncology by Gary H. Lyman, MD, of Fred Hutchinson Cancer Research Center, and colleagues, an ASCO clinical practice guideline update panel made no changes to the 2014 recommendations for sentinel lymph node biopsy in women with early-stage breast cancer. The...

breast cancer

Phase III Trial Shows Improved Progression-Free Survival With Fulvestrant vs Anastrozole in Hormone Receptor–Positive Advanced Breast Cancer

In the international phase III FALCON trial reported in The Lancet, Robertson et al found that progression-free survival was improved with intramuscular fulvestrant (Faslodex) vs oral anastrozole in endocrine therapy–naive women with hormone receptor–positive locally advanced or...

breast cancer

No Significant Benefit of Perindopril or Bisoprolol in Reducing Trastuzumab-Associated Cardiac Remodeling in HER2-Positive Breast Cancer

Use of the angiotensin-converting enzyme inhibitor perindopril or the beta-blocker bisoprolol did not reduce the risk of trastuzumab (Herceptin)-related cardiac remodeling in women with HER2-positive early breast cancer, according to a Canadian trial reported by Pituskin et al in the Journal of...

breast cancer

Equivalent Response Rates With Trastuzumab or Trastuzumab Biosimilar Plus Taxane in HER2-Positive Metastatic Breast Cancer

In part 1 of a phase III equivalence trial reported in JAMA, Rugo et al found that treatment with trastuzumab (Herceptin) or a proposed trastuzumab biosimilar in combination with a taxane produced similar overall response rates in patients with previously untreated metastatic HER2-positive breast...

breast cancer

Assessment of Therapeutic Response by Intrinsic Subtype for HER2-Positive Breast Tumors

In an analysis of outcomes in the North Central Cancer Treatment Group/Alliance N9831 trial reported in the Journal of the National Cancer Institute, Perez et al found that patients with tumors scored as HER2-enriched or luminal subtype derived a recurrence-free survival benefit from the addition...

breast cancer

Obesity/Overweight and Lower Activity Level May Increase Risk of Taxane-Induced Neuropathy in Women With Invasive Breast Cancer

Greenlee et al found that obesity, overweight, and low levels of moderate-to-vigorous physical activity were associated with an increased risk of taxane-related peripheral neuropathy in women with invasive breast cancer, according to a study reported in the Journal of the National Cancer Institute. ...

breast cancer

Study Finds Serum DNA Methylation an Early Marker of Response and Survival in Metastatic Breast Cancer

In the Translational Breast Cancer Research Consortium (TBCRC) 005 prospective biomarker study, reported in the Journal of Clinical Oncology by Visvanathan et al, a cumulative methylation index was found to be predictive of progression-free survival, overall survival, and disease status at first...

breast cancer

Study Shows Modestly Reduced Breast Cancer Recurrence Risk With Increased Protein Intake Independent of Tumor Insulin Receptor Status

In an analysis in the Nurses’ Health Study population reported in the Journal of Clinical Oncology, Holmes et al found modest reductions in the risk for distant recurrence of breast cancer with greater protein intake. No associations with intake of essential amino acids, branched-chain amino...

breast cancer

Link Between Previous Treatment for Depression and Increased Risk of Receiving Nonguideline Treatment in Early-Stage Breast Cancer

Women with early-stage breast cancer previously treated for depression were more likely to receive nonguideline treatment for breast cancer, “probably contributing to poorer overall and cancer-specific survival,” according to a nationwide Danish cohort study reported in the Journal of...

breast cancer

Phase III Trial Shows Ado-Trastuzumab Emtansine Noninferior to Trastuzumab/Taxane in HER2-Positive Breast Cancer

In the phase III MARIANNE trial reported in the Journal of Clinical Oncology, Perez et al found that ado-trastuzumab emtansine (formerly known as T-DM1; Kadcyla) was associated with noninferior progression-free survival compared with trastuzumab (Herceptin) plus taxane in patients with...

breast cancer

Phase III Trial Shows Improved PFS With Addition of Palbociclib to Letrozole in ER-Positive, HER2-Negative Breast Cancer

In the phase III PALOMA-2 trial reported in The New England Journal of Medicine, Finn et al found that the addition of palbociclib (Ibrance) to letrozole significantly improved progression-free survival in postmenopausal women with previously untreated advanced estrogen receptor–positive,...

breast cancer

Breast Cancer Hormonal Therapy Persistence and Adherence Better in Black, Hispanic, and White Women With vs Without Medicare D Prescription Subsidies

In a study reported in the Journal of Clinical Oncology, Biggers et al found that persistence and adherence with hormonal therapy for breast cancer were greater among black, Hispanic, and white women with vs without low-income prescription subsidies in Medicare Part D. The study involved 25,111...

breast cancer

Mammography-Detected Small Breast Cancers May Represent Overdiagnosis, With Survival Gains Reflecting Improved Systemic Therapy

In a study using SEER (Surveillance, Epidemiology, and End Results) data reported in The New England Journal of Medicine, Welch et al found that screening mammography has resulted in a substantial increase in detection of small breast tumors, many of which represent overdiagnosis, accompanied by...

breast cancer

Genetic Markers Associated With Pathologic Complete Response to Neoadjuvant Therapy Identified in HER2-Positive Breast Cancer

In an analysis reported in JAMA Oncology, Fumagalli et al identified genetic markers associated with pathologic complete response among women with early-stage HER2-positive breast cancer receiving neoadjuvant therapy in the phase III NeoALTTO trial. Study Details In the NeoALTTO trial, 455...

breast cancer

First-Line Ribociclib Prolongs Progression-Free Survival in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

In a phase III trial reported at the recent European Society for Medical Oncology Congress and in The New England Journal of Medicine by Hortobagyi et al, first-line treatment with ribociclib, a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), resulted in significantly longer...

breast cancer

Women With Breast Cancer Report Primary Care Physician Involvement in Care and Participation in Decision-Making

Most women with breast cancer reported high primary care physician quality, engagement, and communication, with a minority reporting high levels of primary care physician participation in treatment decisions, according to a study reported by Wallner et al in the Journal of Clinical Oncology....

breast cancer

ASCO/ASTRO/SSO Develop Focused Guideline Update on Postmastectomy Radiotherapy

As reported by Recht et al in the Journal of Clinical Oncology, a joint ASCO, American Society for Radiation Oncology (ASTRO), and Society of Surgical Oncology (SSO) panel has developed a focused guideline update of the ASCO guideline on postmastectomy radiotherapy. A recent Cancer Care Ontario...

breast cancer

Effect of G-CSF Prophylaxis With Chemotherapy for Breast Cancer on Neutropenia-Related Hospitalization

In an analysis of commercial U.S. health plan data reported in the Journal of Clinical Oncology, Agiro et al found that granulocyte colony-stimulating factor (G-CSF) primary prophylaxis was associated with a “low-to-modest’’ benefit in preventing neutropenia-related...

breast cancer

10-Year Risk of Invasive Breast Cancer After Diagnosis of Atypical Ductal Hyperplasia by Needle Biopsy

The cumulative estimated risk of invasive breast cancer at 10 years after diagnosis of atypical ductal hyperplasia by core-needle biopsy was approximately 5%, according to a study reported by Menes et al in JAMA Oncology. The 10-year risk was 6.7% with atypical ductal hyperplasia diagnosed by...

breast cancer
gynecologic cancers

Study Suggests Role of Bilateral Oophorectomy in Preventing Premenopausal Breast Cancer in BRCA2- but Not BRCA1-Mutation Carriers

Bilateral oophorectomy was associated with prevention of premenopausal breast cancer in BRCA2- but not BRCA1-mutation carriers, according to a study reported by Kotsopoulos et al in the Journal of the National Cancer Institute. The study included 3,722 women with BRCA mutations in a prospective...

breast cancer

Discrepancies Between Current ASCO-CAP Guidelines on HER2 Amplification Testing and Designations in BCIRG Trials

In an analysis reported in the Journal of Clinical Oncology, Press et al found notable discrepancies between recent ASCO–College of American Pathologists (ASCO-CAP) changes in the recommendations for evaluation of HER2 amplification by fluorescent in situ hybridization (FISH) and FISH scores...

breast cancer

Psychosocial Adjustment, Breast Cancer–Specific Distress in Adolescent Girls From BRCA1/2-Positive and Breast Cancer Families

Adolescent girls from BRCA1/2-positive and breast cancer families appear to have higher self-esteem and similar psychosocial adjustment compared with their peers but experience greater breast cancer–specific distress and perceived risk of breast cancer. Bradbury et al reported these findings...

breast cancer

Study Finds Chemotherapy May Be Avoidable in Women With Early Breast Cancer at High Clinical but Low Genomic Risk on 70-Gene Signature Assay

In a phase III trial (MINDACT) reported in The New England Journal of Medicine, Cardoso et al found that adjuvant chemotherapy may be avoidable in women with early-stage breast cancer who are at high clinical risk but low genomic risk as determined by the 70-gene signature assay (MammaPrint)....

breast cancer

Overall Survival With Bevacizumab/Capecitabine Noninferior vs Bevacizumab/Paclitaxel in HER2-Negative Breast Cancer

As reported in The Lancet Oncology by Zielinski et al, the final results of the phase III TURANDOT trial showed that overall survival with first-line bevacizumab (Avastin)/capecitabine was noninferior vs bevacizumab/paclitaxel in per-protocol analysis among patients with advanced HER2-negative...

breast cancer

Reference Laboratory Identifies Change in Pattern of Breast Cancer HER2 Fluorescence in Situ Hybridization Results

The most recent (2013) ASCO/College of American Pathologists (AC) guidelines for HER2 testing resulted in different rates of HER2 positivity compared with the use of the U.S. Food and Drug Administration (FDA) or 2007 AC guidelines, according to a study reported in the Journal of Clinical Oncology...

breast cancer
issues in oncology

Potential Link Between Obesity and Cardiotoxicity From Anthracyclines Alone or With Trastuzumab for Breast Cancer

Obesity and being overweight were associated with an increased risk of cardiotoxicity in women receiving treatment with anthracyclines and sequential anthracyclines/trastuzumab (Herceptin) for breast cancer, according to a systematic review and meta-analysis reported in the Journal of Clinical...

breast cancer
solid tumors

Neoadjuvant Veliparib/Carboplatin and Neratinib ‘Graduate’ From Adaptive Randomization I-SPY 2 Trial in Early Breast Cancer

As reported by Rugo et al and Park et al in The New England Journal of Medicine, the adaptive randomization phase II I-SPY 2 trial has shown that the addition of veliparib/carboplatin and the addition of neratinib to standard neoadjuvant therapy have met criteria predictive of success in a phase...

Advertisement

Advertisement



Advertisement